Protalix BioTherapeutics Inc. Reports Strong Q2 2025 Financial Performance

In a significant development for the biotechnology sector, Protalix BioTherapeutics Inc. (NYSE American: PLX) has announced robust financial results for the second quarter of 2025. The company, renowned for its innovative plant cell culture technology and bioreactor systems, reported a 16% increase in revenues from goods, reaching $15.4 million compared to the same period last year. This growth is primarily attributed to heightened sales of Elfabrio® in the $2.3 billion global Fabry disease market.

The company’s financial turnaround is noteworthy, with a net income of $164,000, a stark contrast to the net loss of $2.2 million reported in Q2 2024. This positive shift underscores Protalix’s strategic advancements and operational efficiencies in the competitive biopharmaceutical landscape.

Key Developments and Strategic Moves

In addition to financial achievements, Protalix has made significant organizational changes. Gilad Mamlok has been appointed as the new Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin. This leadership transition is expected to further strengthen the company’s financial strategy and operational execution.

Moreover, Protalix’s inclusion in the Russell 3000® and Russell 2000® Indexes marks a milestone, enhancing its visibility and credibility in the investment community. This recognition is a testament to the company’s growth potential and its pivotal role in the biotechnology industry.

Conference Call and Business Update

Protalix BioTherapeutics is set to host a conference call and webcast today at 8:30 a.m. EDT, providing further insights into its financial results and strategic direction. Dror Bashan, President and Chief Executive Officer, highlighted a 50% increase in revenues from selling goods in the first half of 2025 compared to the same period in 2024, reflecting the company’s strong market position and product demand.

Market Performance and Outlook

Despite a slight miss in GAAP EPS of $0.00 by $0.03, Protalix’s revenue of $15.66 million exceeded expectations by $2.18 million. The company’s stock closed at $1.61 on August 12, 2025, with a 52-week high of $3.1 and a low of $0.89. With a market capitalization of approximately $128.17 million, Protalix continues to navigate the challenges and opportunities within the biotechnology sector.

Analysts project a promising outlook for Protalix, with an expected EPS of $0.040 for the recent quarter, a significant improvement from the loss of $0.030 per share in the same period last year. Revenue forecasts suggest a 15.29% increase, with projections of $15.5 million against $13.5 million in the previous year.

As Protalix BioTherapeutics Inc. advances its strategic initiatives and explores new therapeutic applications, the company remains a key player in the biotechnology industry, poised for continued growth and innovation.